IKBKB expression in clear cell renal cell carcinoma is associated with tumor grade and patient outcomes

BARTLOMIEJ E. KRAZINSKI¹, ANNA E. KOWALCYK¹, AGNIESZKA SLIWINSKA-JEWSIEWICKA¹, JEDRZEJ GRZEGRZOLKA², JANUSZ GODLEWSKI¹, PRZEMYSLAW KWIATKOWSKI¹, PIOTR DZIEGIEL²,³, ZBIIGNIEW KMIEC¹,⁴ and JOLANTA KIEWISZ³

¹Department of Human Histology and Embryology, University of Warmia and Mazury in Olsztyn, 10-082 Olsztyn; ²Department of Human Morphology and Embryology, Division of Histology and Embryology, Wroclaw Medical University, 50-368 Wroclaw; ³Department of Physiotherapy, Wroclaw University School of Physical Education, 51-612 Wroclaw; ⁴Department of Histology, Medical University of Gdansk, 80-211 Gdansk, Poland

Received June 21, 2018; Accepted October 24, 2018

DOI: 10.3892/or.2018.6872

Abstract. Inhibitor of nuclear factor kappa B kinase subunit B (IKBKB or IKKβ) is a key activator of the nuclear factor κB transcription factor pathway. Increased expression and/or aberrant activity of IKBKB have been observed in various types of human cancer. Three independent techniques, reverse transcription-quantitative polymerase chain reaction, western blotting and immunohistochemistry, were used to demonstrate that IKBKB expression is decreased in clear cell renal cell carcinoma (ccRCC). Notably, the patients with upregulated IKBKB protein expression were characterized by higher nuclear grade tumors and significantly shorter survival. The findings indicate that IKBKB protein may be of clinical relevance in ccRCC, serving as a marker of poor prognosis and as potential target for adjuvant chemotherapies. Further studies are required to validate the prognostic and predictive value of IKBKB.

Introduction

Renal cell carcinomas (RCCs) are a heterogeneous group of different kidney tumors, with clear cell RCC (ccRCC) being the most prevalent histological subtype (1,2). The majority of sporadic ccRCC cases are characterized by loss or inactivation of von Hippel-Lindau (VHL) tumor-suppressor gene, resulting in accumulation of hypoxia inducible factors (HIFs) and over-expression of HIF-driven genes that are partially responsible for cell proliferation, angiogenesis and tumor growth (1,2). If diagnosed at early stages, clear cell tumors are usually curable by surgical treatment; whereas advanced ccRCC are characterized by worse prognosis compared to non-clear cell subtypes of RCC (3). The majority patients usually report no symptoms and approximately a third of patients with ccRCC are diagnosed at the metastatic stage of the disease. Despite surgical treatment of primary disease, approximately half of the patients with primarily localized tumors will eventually develop metastases or recurrent disease (1,3). The molecular background of ccRCC has been extensively studied resulting in better understanding of the ccRCC molecular background and development of novel therapeutic strategies (2,4). However, the benefits of adjuvant treatments for advanced or metastatic ccRCC still require improvement (1). In addition, there is a lack of reliable molecular prognostic and predictive markers that could be routinely used for improved patient monitoring and targeted as effective treatment strategies (1,5).

Nuclear factor-κB (NF-κB) is a protein complex that controls the expression of genes involved in immune response and cell survival and is often upregulated in human cancer (6,7) including RCC (8). The classical (canonical) NF-κB pathway comprises heterodimer of the transcription factors RelA/p50. In the resting state, heterodimers are sequestered in the cytoplasm by NF-κB inhibitors (IκB). Canonical NF-κB signaling can be induced by pro-inflammatory mediators including lipopolysaccharides, cytokines or CD40 ligand (6,7). Inhibitor of nuclear factor κB kinase subunit B (IKBKB or IκKβ) is part of the IκB kinase (IKK) complex that activates the transcription factor NF-κB (9). Upon activation, IKBKB phosphorylates IκB leading to its ubiquitination and degradation, releasing RelA/p50 from inhibition. Following translocation to the nucleus, RelA/p50 binds to κB sites within promoters and regulates the transcription of target genes to increase the expression of pro-survival and pro-inflammatory factors (6,7,9). Generation of IKBKB−/− mice and further experimentation performed using IKBKB-deficient cells demonstrated that this protein is essential for activation of NF-κB and functions as a dominant kinase in the canonical NF-κB cascade (6,10,11).

Sustained activation, defective regulation and overexpression of proteins of the NF-κB pathway is observed in certain tumors and tumor-derived cell lines, and is associated with the malignant phenotype in the majority of cases (12). NF-κB
transcription factors have been extensively researched because of their involvement in stromal communication with cancer cells and role in establishing the tumor microenvironment. Cancer cells, a variety of non-cancerous tumor-associated immune cells and fibroblasts exhibit altered NF-κB signaling, which is often associated with intratumoral immunosuppression and development of multidrug resistance (7,12). In addition to its major role in the activation of NF-κB pathway, IKKB was demonstrated to be phosphorylated NF-κB-unrelated factors, including tumor suppressor p53 or forkhead box O3 transcription factors, targeting them for degradation by the ubiquitin-proteasome pathway (13,14). It was also demonstrated that IKKB is a target for prolyl hydroxylase-mediated hydroxylatation and, therefore, hypoxia increases the expression and activity of IKKB in cultured cancer cells (15); whereas the protein product of VHL tumor suppressor gene (pVHL) negatively regulates IKKB (16).

In the present study, the expression of IKKB in tumors and matched non-cancerous renal tissues of patients with ccRCC was investigated. The association of IKKB protein expression with clinicopathological parameters and survival of ccRCC patients was assessed.

Patients and methods

Patients and the collection of samples. Specimens were obtained from postoperative material of 66 patients with histologically confirmed ccRCC (33 men and 33 women; mean age ± standard deviation, 63.2±10.6; range 27-83 years) operated on at the Department of Oncological Surgery, Warmia and Mazury Oncological Center in Olsztyn (Olsztyn, Poland) between March 2010 and July 2014. None of patients had a second neoplastic disease or had previously undergone chemoradiotherapy. The specimens of the tumor and matched, macroscopically unchanged renal tissue were obtained from surgically resected kidney. Specimens for RNA or protein extraction were immediately frozen in liquid nitrogen and stored at -80°C until further analysis. Tumor and kidney fragments for histological and immunohistochemical studies were fixed in 4% buffered formaldehyde for 48-72 h at room temperature, dehydrated using a series of alcohol solutions in ascending concentrations (50, 60, 70, 85 and 99.8%; at room temperature), cleared with xylene at room temperature, fixed in 4% buffered formaldehyde for 48-72 h at room temperature, dehydrated using a series of alcohol solutions in ascending concentrations (50, 60, 70, 85 and 99.8%; at room temperature), cleared with xylene at room temperature, processed into paraffin blocks. Clinical staging was based on the American Joint Committee on Cancer criteria (17). The tumor nuclear grading was characterized by a pathologist according to the Fuhrman system (18). Clinicopathological and demographic data of the patients as well as their overall survival (OS) records were collected during the study. The median follow-up time was 40.6 months.

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted and reverse transcribed using the method described previously (19). The IKKB transcripts in tissue homogenates were determined by qPCR and normalized to peptidylprolyl isomerase A (PPIA) and TATA box binding protein (TBP) mRNAs using TaqMan Fast Advanced Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.). qPCR reactions were performed using ABI 7500/7500 Fast Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the protocol described by Kowalczyk et al (20). The following thermocycling conditions were used: polymerase activation for 20 sec at 95°C, then 40 cycles of denaturation for 3 sec at 95°C and annealing/extension for 30 sec at 60°C. The ΔΔCT method (21) was used to determine the fold differences [relative quantification (RQ)] in expression between the paired samples of ccRCC and unchanged renal tissue. On the basis of IKKB RQ (ccRCC vs. renal tissue), specimens were divided into two groups, regarded as IKKB ‘upregulated’ (RQ≥1.5) and ‘no change and downregulated’ (RQ<1.5).

Protein extraction, SDS-PAGE and western blot analysis. Procedures were performed according to the method described previously (22) with some modifications. Briefly, the samples were homogenized in radioimmunoprecipitation lysis buffer supplemented with 1:100 protease inhibitor cocktail, 1:100 phosphatase inhibitor cocktail and 5 mM EDTA (Sigma-Aldrich; Merck, KGaA, Darmstadt, Germany). Homogenates were centrifuged twice at 9,000 x g for 10 min at 4°C. The protein content in the supernatant was determined by the Bradford method. Protein lysates were denatured for 5 min at 95°C and loaded on a 10% polyacrylamide gel (30 µg/lane), separated (10 mA/gel during migration in stacking gel, then 15 mA/gel), transferred onto polyvinylidene difluoride membrane (Roche Diagnostics GmbH, Mannheim, Germany) and blocked in 5% nonfat dry milk for 2 h at room temperature. The level of protein in homogenates of paired tumor and renal tissue specimens was determined using rabbit anti-human antibodies against IKKB (1:1,000; cat. no. sc-7329; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and actin (ACTB; 1:100; cat. no. A2066; Sigma-Aldrich; Merck, KGaA) as the internal loading control. Following overnight incubation at 4°C with primary antibodies, the membranes were treated with polyclonal horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibodies (diluted 1:40,000; cat. no. A0545; Sigma-Aldrich; Merck, KGaA) for 60 min at room temperature, developed with SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Inc.) and visualized with G:BOX iChemi XR imaging system (Syngene Europe, Cambridge, UK). Band intensity was quantified using ImageJ software (version 1.50i; National Institutes of Health, Bethesda, MD, USA). IKKB/ACTB optical density (OD) ratios were used to determine fold differences in expression between the paired samples of ccRCC and unchanged renal tissue. On the basis of their relative IKKB OD ratios (ccRCC vs. renal tissue) specimens were divided into two groups, regarded as IKKB ‘upregulated’ (OD ratios ≥1.5) and ‘no change and downregulated’ (OD ratios <1.5).

Immunohistochemistry (IHC) and evaluation of immunoreactivity. IKKB immunostaining of the tumor and non-cancerous kidney 4-µm-thick paraffin sections was performed using the Autostainer Link 48 supplied with EnVision FLEX reagents (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) according to the previously described method (23). Rabbit antibody directed against human IKKB (1:1,000; cat. no. sc-7329; Santa Cruz Biotechnology, Inc.) was applied for 20 min at room
temperature whereas the negative controls were performed by
omitting the primary antibody. The sections were counterstained
with EnVision FLEX Hematoxylin (ready-to-use solution; Dako;
Agilent Technologies, Inc.) for 5 min at room temperature. The
IKBKB immunoreactivity was evaluated using an Olympus
BX53 light microscope (Olympus Corporation, Tokyo, Japan)
by two independent pathologists in a blinded manner regarding
the clinicopathological data of the patients. In doubtful cases,
re-evaluation was performed until a consensus was achieved.
Immunoeexpression of IKBKB was assessed in the cytoplasm
of cancer cells and non-transformed, normal epithelial cells of
the proximal convoluted tubules (PCTs). IKBKB immunoreac-
tivity was evaluated according to the immunoreactive score (IRS)
of Remmele and Stegner (24). The IRS scale is based on the
percentage of cells exhibiting positive reaction (0 points, absence
of cells with positive reaction; 1 point, 1-10%; 2 points, 11-50%;
3 points, 51-80%; 4 points, >80% cells with positive reaction)
and reaction intensity (0, no reaction; 1, low intensity reaction;
2, moderate intensity reaction; 3, intense reaction). The final
score is the result of multiplication of both parameters and ranges
from 0 to 12 points). On the basis of their relative IRS ratios
specimens were divided into two groups regarded as ‘upregu-
lated’ (IRS ratio ≥1.5 and tumor-only positive specimens) and
‘no change or downregulated’ IKBKB immunoreactivity (IRS
ratio <1.5 or renal-only positive specimens).

Cancer genomics data from The Cancer Genome Atlas
(TCGA). A dataset containing results of RNA-Seq analysis
of 469 primary nephrectomy specimens from patients with
histologically confirmed ccRCC (2) was investigated for
mutations, putative copy-number alterations and expression
levels of IKBKB using a cBio Cancer Genomics Portal (25).
The IKBKB expression data were queried using 1.5-fold
change as a z-score threshold value.

Statistical analysis. Statistical analysis was performed using
Prism 6.04 (GraphPad Software, Inc., La Jolla, CA, USA)
and Statistica 13.1 (Statsoft, Tulsa, OK, USA). The IKBKB
expression levels are expressed as mean ± standard error.
The differences in IKBKB expression levels between the
paired tumor and unchanged renal tissue specimens were
examined by the Wilcoxon matched-pairs test. Fisher’s exact,
Mann-Whitney U test and Spearman’s rank correlation were
used to assess associations between the patient data and
IKBKB expression levels. Survival curves were plotted according to
the Kaplan-Meier method and the significance of differences in
OS between groups of patients was evaluated by log-rank test.
The uni- and multivariate survival associations were analyzed
using the Cox proportional hazards regression model. P<0.05
was considered to indicate statistically significant difference.

Results

IKBKB expression is downregulated in ccRCC at the mRNA
and protein levels. All tumor and matched unchanged renal
tissue samples of ccRCC patients expressed IKBKB mRNA.
IKBKB mRNA level was reduced or remained unchanged in
63/66 (95.5%), and was elevated in 3/66 (4.5%) ccRCC cases
(Fig. 1A). The average expression level of IKBKB transcript
was significantly decreased in ccRCC compared with the

Figure 1. IKBKB expression in the ccRCC specimens and matched unchanged renal tissues at the mRNA and protein levels were determined by (A) reverse
transcription-quantitative polymerase chain reaction and (B) western blot. Grey bars represent patients revealing not changed or downregulated IKBKB, black
bars represents patients with upregulated IKBKB (left). Average IKBKB expression levels in the ccRCC specimens and unchanged renal tissues at the mRNA
and protein levels (right). ***P<0.001. ccRCC, clear cell renal cell carcinoma; IKBKB, inhibitor of nuclear factor κB kinase subunit B.
IKBKB protein was present in all tested homogenates of tumor and renal tissue as determined by western blotting. The content of IKBKB protein was reduced or remained unchanged in 60/66 (90.9%) ccRCC cases; whereas, it was elevated in 6/66 (9.1%) of tumor homogenates (Fig. 1B). The average IKBKB/ACTB OD was significantly lower in ccRCC samples compared with the corresponding unchanged kidney tissue (OD ratio 0.65±0.10 and 1.00±0.13, respectively; P<0.001; Fig. 1B).

Immunoreactivity of IKBKB was observed in the cytoplasm of cancer cells and PCT epithelial cells of analyzed sections (Fig. 2A-D). In addition to PCT epithelium, the cells of distal convoluted tubules, renal glomeruli and Bowman's capsule from non-cancerous renal tissue sections exhibited weak to moderate cytoplasmic IKBKB immunoreactivity. IKBKB did not exhibit nuclear expression in the tumor or non-cancerous renal tissue. IKBKB immunoreactivity was detected in the cancer cells of 26/50 (52%) ccRCC cases. In the PCT epithelium of matched renal tissue, IKBKB expression was observed in 41/50 (82%) cases. IKBKB protein expression was downregulated in 31/50 (62%), remained unchanged in 13/50 (26%) and was elevated in 6/50 (13%) of ccRCC cases compared with the matched non-cancerous tissue (Fig. 2E). The average IKBKB immunoreactivity was significantly reduced in the tumor cells compared with the PCT epithelial cells of corresponding non-cancerous renal tissues (IRS 1.48±0.25 and 3.02±0.29, respectively; P<0.001; Fig. 2E).

Increased IKBKB immunoreactivity in ccRCC cells is associated with higher nuclear grade. Elevated immunoreexpression of IKBKB protein in cancer cells compared with normal PCT epithelium was positively associated with Fuhrman nuclear grade (P=0.0331; Fisher's exact test; Table I). Furthermore, there was ~2-fold increase in relative immunoreactivity of IKBKB in cancer cells of G3 tumors compared with G1 and G2.
Table I. Associations between demographic and clinicopathological features of patients with ccRCC and relative expression of *IKBKB* at the mRNA and protein levels as determined by reverse transcription-quantitative polymerase chain reaction, western blotting and immunohistochemistry.

<table>
<thead>
<tr>
<th>Clinicopathological feature</th>
<th>Number of cases (%)</th>
<th>IKBKB mRNA RQ (tumor vs. renal tissue)</th>
<th>IKBKB protein OD ratio (tumor vs. renal tissues)</th>
<th>IKBKB relative IR (ccRCC cells vs. PCT epithelium)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;1.5, n (%)</td>
<td>≥1.5, n (%)</td>
<td>P-value</td>
<td>&lt;1.5 n (%)</td>
</tr>
<tr>
<td>Total</td>
<td>66 (100)</td>
<td>63 (95)</td>
<td>3 (5)</td>
<td>60 (91)</td>
</tr>
<tr>
<td>Sex</td>
<td>0.2385</td>
<td>0.6724</td>
<td>0.1919</td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>33 (50)</td>
<td>33 (100)</td>
<td>0 (0)</td>
<td>31 (94)</td>
</tr>
<tr>
<td>Women</td>
<td>33 (50)</td>
<td>30 (91)</td>
<td>3 (9)</td>
<td>29 (88)</td>
</tr>
<tr>
<td>T status</td>
<td>1.0000</td>
<td>1.0000</td>
<td>0.2234</td>
<td></td>
</tr>
<tr>
<td>T1+T2</td>
<td>36 (55)</td>
<td>34 (94)</td>
<td>2 (6)</td>
<td>33 (92)</td>
</tr>
<tr>
<td>T3</td>
<td>30 (45)</td>
<td>29 (97)</td>
<td>1 (3)</td>
<td>27 (90)</td>
</tr>
<tr>
<td>Fuhrman grade</td>
<td>1.0000</td>
<td>1.0000</td>
<td>0.0331</td>
<td></td>
</tr>
<tr>
<td>G1+G2</td>
<td>49 (74)</td>
<td>47 (96)</td>
<td>2 (4)</td>
<td>44 (90)</td>
</tr>
<tr>
<td>G3+G4</td>
<td>17 (26)</td>
<td>16 (94)</td>
<td>1 (6)</td>
<td>16 (94)</td>
</tr>
<tr>
<td>Distant metastases</td>
<td>1.0000</td>
<td>0.5823</td>
<td>0.5756</td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>54 (82)</td>
<td>51 (94)</td>
<td>3 (6)</td>
<td>48 (89)</td>
</tr>
<tr>
<td>M1</td>
<td>12 (18)</td>
<td>12 (100)</td>
<td>0 (0)</td>
<td>12 (100)</td>
</tr>
<tr>
<td>Tumor growth</td>
<td>1.0000</td>
<td>1.0000</td>
<td>0.1841</td>
<td></td>
</tr>
<tr>
<td>Kidney-confined</td>
<td>38 (58)</td>
<td>36 (95)</td>
<td>2 (5)</td>
<td>34 (89)</td>
</tr>
<tr>
<td>Advanced/recurrent</td>
<td>28 (42)</td>
<td>27 (96)</td>
<td>1 (4)</td>
<td>26 (93)</td>
</tr>
</tbody>
</table>

Significant P-values (P<0.05) are in bold. ccRCC, clear cell renal cell carcinoma; IKBKB, inhibitor of nuclear factor κB kinase subunit B; RQ, relative quantification; OD, optical density; IR, immunoreactivity; PCT, proximal convoluted tubule.
KRAZINSKI et al.: IKBKB IN CLEAR CELL RENAL CELL CARCINOMA

Table II. Correlation between demographic and clinicopathological features of patients with ccRCC and relative expression of IKBKB at the mRNA and protein levels as determined by reverse transcription-quantitative polymerase chain reaction, western blotting and immunohistochemistry.

<table>
<thead>
<tr>
<th>Variable</th>
<th>IKBKB mRNA RQ (tumor vs. renal tissue, n=66)</th>
<th>IKBKB protein OD ratio (tumor vs. renal tissues, n=66)</th>
<th>IKBKB relative IR (ccRCC cells vs. PCT epithelium, n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Spearman’s ρ</td>
<td>P-value</td>
<td>Spearman’s ρ</td>
</tr>
<tr>
<td>Age</td>
<td>-0.2291</td>
<td>0.0643</td>
<td>0.1107</td>
</tr>
<tr>
<td>Tumor size</td>
<td>-0.0366</td>
<td>0.7704</td>
<td>0.0402</td>
</tr>
</tbody>
</table>

ccRCC, clear cell renal cell carcinoma; IKBKB, inhibitor of nuclear factor κB kinase

G2 tumors (0.92±0.17 vs. 0.54±0.08; P=0.0304; Mann-Whitney U test). No other correlations between IKBKB expression levels and demographic or clinicopathological parameters of the patients were identified (Tables I and II).

Upregulated IKBKB protein expression is associated with unfavorable prognosis. Kaplan-Meier plots presenting the OS of patients with ccRCC grouped according to the expression levels of IKBKB are presented in the Fig. 3. Increased of IKBKB protein expression was significantly associated with shorter OS of patients with ccRCC (median 25.7 months for upregulated group vs. ≥85.3 months for not changed or downregulated IKBKB protein content; P=0.0099; Fig. 3A). The expression of IKBKB transcript and immunoreactivity of IKBKB in cancer cells did not correlate with OS of patients with ccRCC (Fig. 3B and C, respectively). Univariate Cox proportional hazards regression revealed that IKBKB protein level, T-status of the primary tumor, nuclear grade, presence of distant metastases and advanced/recurrent disease were associated with OS of the patients (Table III). The subsequent multivariate analysis confirmed that higher IKBKB protein level [hazard ratio (HR)=5.50; P=0.0020; Table III] and with the presence of distant metastases (HR=3.99; P=0.0182; Table III) achieved a status of independent prognostic factors in ccRCC.

TCGA dataset analysis. Analysis of cancer genomics data provided by TCGA revealed that none of 469 ccRCC cases included in the dataset contained IKBKB sequence mutation. Copy number alterations were reported only in four ccRCC cases (0.9%). The expression level of IKBKB mRNA was downregulated in 31/469 (6.6%) and upregulated in 28 (6%) of queried ccRCC samples while the levels of IKBKB protein in the tumor did not differ from those in the matching renal tissue.

Discussion

In the present study, three independent techniques (RT-qPCR, western blot analysis and IHC) were used to demonstrate that the expression level of IKBKB is decreased in ccRCC. The majority of the analyzed tumor specimens exhibited reduced levels of IKBKB mRNA and protein. However, an upregulated IKBKB protein level was associated with higher nuclear grade of the tumor and significantly shorter survival, suggesting an oncogenic role of this kinase in ccRCC.
Table III. Univariate and multivariate Cox regression analysis of the overall survival rates associated with different prognostic variables in patients with clear cell renal cell carcinoma.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Univariate Cox regression</th>
<th>Multivariate Cox regression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI) P-value</td>
<td>HR (95% CI) P-value</td>
</tr>
<tr>
<td>IKBKB mRNA RQ (upregulated vs. no change/downregulated)</td>
<td>0.47 (0.06-3.50) 0.4645</td>
<td>5.50 (1.86-16.2) 0.0020</td>
</tr>
<tr>
<td>IKBKB protein OD ratio (upregulated vs. no change/downregulated)</td>
<td>4.61 (1.70-12.5) <strong>0.0026</strong></td>
<td>3.12 (0.87-11.2) 0.0815</td>
</tr>
<tr>
<td>IKBKB immunoreactivity (upregulated vs. no change/downregulated)</td>
<td>1.03 (0.24-4.49) 0.9634</td>
<td>1.65 (0.63-4.33) 0.3112</td>
</tr>
<tr>
<td>Sex (women vs. men)</td>
<td>0.70 (0.32-1.51) 0.3604</td>
<td>3.99 (1.27-12.6) <strong>0.0182</strong></td>
</tr>
<tr>
<td>Age (years)</td>
<td>0.99 (0.95-1.03) 0.5269</td>
<td>0.58 (0.19-1.77) 0.3412</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td>1.17 (1.05-1.31) <strong>0.0052</strong></td>
<td>1.07 (0.88-1.28) 0.5094</td>
</tr>
<tr>
<td>Depth of invasion (T3 vs. T1+T2)</td>
<td>4.31 (1.80-10.3) <strong>0.0010</strong></td>
<td>3.12 (0.87-11.2) 0.0815</td>
</tr>
<tr>
<td>Fuhrman grade (G3 vs. G1+G2)</td>
<td>3.33 (1.49-7.44) <strong>0.0034</strong></td>
<td>1.65 (0.63-4.33) 0.3112</td>
</tr>
<tr>
<td>Distant metastases (M1 vs. M0)</td>
<td>2.78 (1.19-6.50) <strong>0.0185</strong></td>
<td>3.99 (1.27-12.6) <strong>0.0182</strong></td>
</tr>
<tr>
<td>Tumor growth (advanced/recurrent vs. kidney-confined)</td>
<td>2.57 (1.08-5.20) <strong>0.0318</strong></td>
<td>0.58 (0.19-1.77) 0.3412</td>
</tr>
</tbody>
</table>

Median follow-up time, 40.6 months. Significant P-values (P<0.05) are in bold. HR, hazard ratio; CI, confidence interval; RQ, relative quantification; OD, optical density.

Previous studies using patients with RCC, cell lines and xenograft animal models of RCC identified IKBKB as a factor associated with the progression of the disease and poor patient outcomes. A dataset from TCGA containing 469 ccRCC cases revealed that copy number alterations of IKBKB were rare in this cancer (~1% of tumors), and no alterations in the IKBKB sequence were reported in this dataset (2,25). NF-κB pathway genes rarely contain mutations in cancer (12). Constitutive activation of NF-κB in certain cancers is usually mediated by alterations of upstream regulators and/or altered expression levels of NF-κB-associated genes (12). In the current study, IKBKB expression was also investigated using the TCGA data provided by the cBio Cancer Genomics Portal (2,25) setting a z-score threshold for 1.5-fold change. This evaluation revealed that the expression level of IKBKB transcript determined by RNA-Seq was downregulated in 7% and upregulated in 6% of ccRCC cases, while IKBKB protein levels measured by reverse-phase protein array remained unaltered in all 469 samples included in the study (2,25). Although these expression data are not in line with the results of the current study, this may be attributed to different sensitivities and specificities of methods used. However, the prognostic significance of IKBKB reported in this study is in accordance with analyses based on previously published study by Peri et al (26). Meta-analysis of ccRCC expression datasets identified a subset of genes including IKBKB and NF-κB mediators, matrix metalloproteinase 9, proteasome subunit β 9 and superoxide dismutase 2, whose elevated expression levels were associated with worse patient outcomes (26). Another study established a model linking pVHL loss to increased activation of NF-κB, potentially elucidating a previously reported observation that loss of may be associated with the chemoresistance of ccRCC to tumor necrosis factor therapy (27). Recently, it has been reported that IKBKB protein may indirectly have a role in stabilizing HIF1α and HIF2α in RCC cells via activation of NF-κB essential modulator (NEMO) protein, a regulatory subunit of the IKK complex (28). In addition, it was demonstrated that the degree of NEMO protein expression was downregulated in 62.8% tumor samples derived from 250 patients with ccRCC, and it was positively associated with the progression of ccRCC (28). This observation seems to be analogous to the finding that IKBKB immunoreactivity was decreased in the majority of analyzed ccRCC specimens, while increased IKBKB protein expression was associated with higher tumor grade and poorer patient outcomes. However, additional studies are required to investigate unknown links between the IKBKB and NEMO proteins and potential common mechanisms underlying their altered expression in ccRCC.

Beneficial effects of decreased IKBKB expression and/or IKBKB protein activity on the effectiveness of different anti-cancer approaches were reported previously (29). Treatment of metastatic RCC cell lines, ACHN and SN12K1, with an anti-oxidant agent, pyrrolidine dithiocarbamate, decreased expression level of IKBKB and other components of NF-κB signaling, as assessed by western blotting (30). The resulting inhibition of NF-κB pathways exerted anti-proliferative, pro-apoptotic and anti-angiogenic effects in the tested cell lines (30,31) and sensitized them to cisplatin treatment (32). Further experiments performed in a xenograft animal model of RCC demonstrated that the antioxidant treatment reduced cancer cell proliferation and attenuated tumor progression, with decreased expression of NF-κB proteins and upstream kinases, IKBKB and IKKA (33). Notably, accumulation of reactive oxygen species in the kidneys of superoxide-deficient mice resulted in decreased expression of IKBKB (34), suggesting that the influence of oxidative stress on expression of NF-κB-associated genes is tissue- or disease-specific. Another study performed in RCC cell lines demonstrated that IKBKB and RelA (p65) were required for the oncogenic properties of microRNA-21 (miR-21) in ACHN cells (35). In turn, miR-21 indirectly increased IKBKB phosphorylation, which upregulated NF-κB and mechanistic target of rapamycin complex 1 signaling, resulting in enhanced proliferation, migration and invasiveness of ACHN and 786-O
cell lines (35,36). Transfection of RCC cell lines with a plasmid expressing IKKBKB attenuated sunitinib-induced p53 promoter transcriptional activity (37). These reports suggest that increased IKKB content in cancer cells can compromise the effectiveness of anticancer therapy, suggesting potential usefulness of IKKBKB as both prognostic and predictive marker in ccRCC.

Altered IKKB expression and/or IKKB kinase activity were previously reported to be associated with the occurrence and progression of several types of human cancer, including breast cancer, pancreatic cancer, thyroidal C-cells carcinoma, acute myeloid leukemia and ovarian cancer (7,8,12,29,38). However, the available data concerning IKKBKB expression are inconclusive. IKKBKB transcript levels were significantly upregulated in human hepatocellular carcinoma compared with adjacent normal tissue (39). Cultured Hs578T breast cancer cells exhibited aberrant expression and activity of IKKBKB compared with untransformed mammary epithelial cells (40). Reduced IKKBKB expression were demonstrated in glioblastoma tissues at the mRNA and protein levels (41). However, downregulation of IKKBKB was attributed to microglia/macrophages infiltrating advanced glioblastoma tumors, indicating the important role of this kinase for the local microenvironment and antitumor response (41).

In conclusion, to the best of our knowledge, the present study is the first comprehensive investigation analyzing IKKBKB expression at the mRNA and protein levels in a cohort of patients with ccRCC. The results suggest that the three techniques applied to determine the IKKBKB expression, RT-qPCR, western blotting and IHC, should be used as a complementary rather than alternative methods. However, additional methodological studies are required to compare these and other available assays before conclusions are made. The number of patients included in the study was enough to disclose associations of IKKBKB protein expression level with clinicopathological parameters and survival of patients with ccRCC. Therefore, the findings of the present study demonstrate that the expression of IKKBKB protein may be of clinical relevance in ccRCC. The elevated content of IKKBKB in the ccRCC tumor tissue may be useful as a potential marker of prognosis, and suggests that the application of anti-NF-κB treatments may sensitize ccRCC cells to certain adjuvant therapies. Further studies using a larger number of patients are required to support this suggestion, and validate prognostic or predictive value of IKKBKB in ccRCC.

Acknowledgements

The authors wish to thank Dr Aleksandra Piotrowska from the Department of Human Morphology and Embryology, Division of Histology and Embryology, Wroclaw Medical University (Wroclaw, Poland) for technical support.

Funding

This study was supported by the National Science Centre (Poland; grant no. 2012/05/B/NZ4/01832).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

BEK, JK and ZK designed the study, analyzed and interpreted the results; BEK and JK wrote the manuscript draft; ZK corrected the final version of the manuscript; JGo and PK collected clinical samples; JGo collected clinicopathological and survival data; BEK, JK, AEK, ASJ performed qPCR and western blot assays; JGr and PD performed IHC and evaluated immunoreactivity; BEK performed the statistical analysis; JK and BEK were managing the project. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Bioethics Committee for Scientific Research at the University of Warmia and Mazury in Olsztyn (Olsztyn, Poland; agreements no. 4/2010 and 44/2011). Written informed consent (as specified in the Declaration of Helsinki) was obtained from each patients included in the study.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

7. Not applicable.


